Navigation Links
Frost & Sullivan Honours LyondellBasell With Customer Value Enhancement Award

LONDON, April 7 /PRNewswire/ -- The 2008 Frost & Sullivan Global Plastics in Medical Devices Customer Value Enhancement Award is presented to LyondellBasell Industries. The award recognises LyondellBasell's status as a one-stop-shop for its customers in the global medical devices market.


"LyondellBasell differentiates itself from many of its competitors by offering customised products and services catering to the global healthcare market," states Frost & Sullivan Research Analyst Hariharan Ramasubramanian. "By adopting such a focused approach to medical devices, LyondellBasell is optimally positioned to create and enhance value for its customers."

LyondellBasell has historically been at the forefront in promoting the use of polyolefins in the medical device industry with its highly popular Purell brand. LyondellBasell offers strong technical support to its customers, while providing them with product certificates necessary for use of its Purell products in medical devices.

"LyondellBasell's Medical Protocol provides its clients with a certified product that complies with the requirements of European and US pharmacopoeia," notes Ramasubramanian. "This enables customers to rapidly get approvals for use of these materials in their medical devices and streamlines the complex validation process governing the use of OEM products in the medical sector."

Moreover, any changes that might be required to the raw material are notified to clients in principle at least 24 months in advance. This is a critical facility that cannot be provided by raw material suppliers that sell standard grades of polyolefins to the market.

The merger of Lyondell and Basell in 2007 has further boosted LyondellBasell's value proposition. This strategic approach has enabled LyondellBasell to provide more regional support to its clients, service markets from local production capabilities as far as possible and leverage on its strong regulatory understanding of the medical device markets to help clients in various regions.

"This combination further solidifies LyondellBasell's position as a one-stop-shop for its customers," says Ramasubramanian. "This is not only in terms of its immense product range, technical and regulatory services, but also because of its ability to provide these on a global basis."

A customer centric approach to the medical device industry also makes it possible for LyondellBasell to identify unmet needs in the industry better than the competition, and to be highly responsive to these requirements through its immense strengths in R&D.

For instance, realising the need and new regulatory requirements for a film polyolefin product line, LyondellBasell introduced new grades of low density polyethylene to this market in 2007, completing its offerings to the injection and blow moulded polyolefins market.

The Customer Value Enhancement Award is presented to the company that has best demonstrated the ability to expand its customer base, while maintaining its existing customer base, with more innovative value creation and enhancement strategies than competing vendors. This Award recognises the company's successful sales entry, customer acquisition and service strategies, and the degree to which those strategies have met customers' stated needs and requirements. Such strategies are expected to significantly improve customer interaction and contribute to customer satisfaction.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About LyondellBasell

LyondellBasell Industries is one of the world's largest polymers, petrochemicals and fuels companies. It is the global leader in polyolefins technology, production and marketing; a pioneer in propylene oxide and derivatives; and a significant producer of fuels and refined products, including biofuels. Through research and development, LyondellBasell develops innovative materials and technologies that deliver exceptional customer value and products that improve quality of life for people around the world. Headquartered in The Netherlands, LyondellBasell ( is privately owned by Access Industries.

    Dr. Michael Luetke, Global Marketing Manager, Healthcare Applications
    Tel: +49 69 30 51 57 24 or

    Media contact - Waldemar Oldenburger, +49 69 305 854 59 or

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit

    Catherine Brassell
    Promotions Coordinator - EMEA
    Best Practices
    P: +44.207.915.7867

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rise in Sleeping Disorders Triggers High Demand for Sleep Service Facilities in Europe, Notes Frost & Sullivan
2. BioMedical Technology Solutions, Inc. a Division of BioMedical Technology Solutions Holdings, Inc. Symbol (BMTL) OTCBB Receives Frost & Sullivans Product Innovation of the Year Award
3. Kenyan Pharmaceutical Industry Can Expect Significant Growth Despite Global Conditions, Finds Frost & Sullivan
4. Tough Recessionary Times, but Frost & Sullivan Believes Its Not All Gloomy for African Healthcare Markets
5. Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia
6. Frost & Sullivan: End-to-End Integration of HD Devices in the Operating Room Ushers in a New Era in Disruptive Technology
7. Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan
8. Frost & Sullivan Accolade for Ferring Pharmaceuticals
9. Leveraging the Third Amendment Ruling the Risk Management Process: Frost & Sullivans Assessment of Regulations for Medical Imaging Equipment in Europe
10. Frost & Sullivan Honours Outstanding Achievements in Healthcare
11. Sentinelle Medical Receives Frost & Sullivan Excellence in Technology Award
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: